Annals of the rheumatic diseases
Journal
Overview
publication venue for
-
Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders..
84.
2025
-
Development of CARRA/PReS-endorsed consensus Core and Expanded Datasets in childhood-onset systemic lupus erythematosus for international registry-based research.
2024
-
Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders.
2024
-
Racial variability in immune responses only partially explains differential systemic sclerosis disease severity.
2024
-
Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Miro-Mur et al..
83.
2024
-
Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al..
83.
2024
-
Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers..
83.
2024
-
Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.
2024
-
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
2023
-
Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO).
2023
-
2023 ACR/EULAR antiphospholipid syndrome classification criteria..
82.
2023
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis..
82.
2023
-
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial..
82.
2023
-
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice..
82.
2023
-
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
2022
-
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis..
80.
2021
-
Charles L Christian: model physician scientist and mentor..
80.
2021
-
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance..
80.
2021
-
Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement..
80.
2020
-
Circulating microbial small RNAs are altered in patients with rheumatoid arthritis..
79.
2020
-
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities..
79.
2020
-
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis..
79.
2020
-
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile..
79.
2019
-
Emergent high fatality lung disease in systemic juvenile arthritis..
78.
2019
-
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout..
78.
2019
-
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures..
78.
2019
-
TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis..
78.
2019
-
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39..
78.
2019
-
Non-classical monocytes as mediators of tissue destruction in arthritis..
77.
2018
-
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies..
77.
2018
-
Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts..
77.
2017
-
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE..
76.
2016
-
Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity..
76.
2016
-
Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus..
76.
2016
-
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study..
76.
2016
-
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis..
75.
2016
-
Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification..
75.
2016
-
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis..
75.
2016
-
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production..
75.
2016
-
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type..
75.
2015
-
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis..
75.
2015
-
The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis..
75.
2015
-
Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration..
75.
2015
-
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period..
74.
2014
-
Neutrophil extracellular traps regulate IL-1β-mediated inflammation in familial Mediterranean fever..
75.
2014
-
Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA..
75.
2014
-
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial..
74.
2014
-
The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis..
73.
2014
-
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study..
74.
2013
-
Racial disparities in knee and hip total joint arthroplasty: an 18-year analysis of national Medicare data..
73.
2013
-
A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients..
73.
2013
-
HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE..
73.
2013
-
Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease..
73.
2013
-
Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study..
73.
2013
-
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus..
73.
2013
-
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis..
72.
2012
-
Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS)..
72.
2012
-
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis..
72.
2012
-
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate..
72.
2012
-
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups..
72.
2012
-
Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients..
72.
2012
-
Incidence and predictors of secondary fibromyalgia in an early arthritis cohort..
72.
2012
-
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice..
71.
2012
-
The role of varus and valgus alignment in the initial development of knee cartilage damage by MRI: the MOST study..
72.
2012
-
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry..
71.
2012
-
Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus..
71.
2011
-
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus..
71.
2011
-
IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction..
71.
2011
-
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial..
71.
2011
-
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort..
71.
2011
-
Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire..
70.
2011
-
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study..
70.
2011
-
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus..
70.
2011
-
Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus..
70.
2011
-
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial..
70.
2011
-
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)..
70.
2010
-
Varus and valgus alignment and incident and progressive knee osteoarthritis..
69.
2010
-
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine..
69.
2010
-
Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis..
68.
2008
-
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade..
68.
2008
-
Is birthweight associated with risk of rheumatoid arthritis? Data from a large cohort study..
68.
2008
-
The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders..
68.
2008
-
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies..
67.
2008
-
Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis..
67.
2008
-
Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome..
67.
2007
-
Histopathological prevalence of subchondral insufficiency fracture of the femoral head..
67.
2007
-
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease..
66.
2007
-
Assessment of the 2006 revised antiphospholipid syndrome classification criteria..
66.
2007
-
Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients..
65.
2006
-
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis..
65.
2006
-
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis..
65.
2006
-
Real world experience with antiphospholipid antibody tests: how stable are results over time?.
64.
2005
-
Increased expression of humanin peptide in diffuse-type pigmented villonodular synovitis: implication of its mitochondrial abnormality..
64.
2004
-
Immunohistochemistry of normal human knee synovium: a quantitative study..
63.
2004
-
Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis..
63.
2004
-
Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis..
63.
2004
-
Long term outcome of catastrophic antiphospholipid syndrome survivors..
62.
2003
-
Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha..
62.
2003
-
Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world"..
61.
2002
-
IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies in systemic lupus erythematosus..
47.
1988
-
Monocyte-induced inhibition of lymphocyte response to phytohaemagglutinin in progressive systemic sclerosis..
42.
1983
-
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City..
80.
2021
-
Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor..
78.
2018
-
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers..
75.
2016
-
The risk of comorbidity..
71.
2012
-
Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial..
66.
2007
-
Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?.
63.
2004
-
Response to: 'Correspondence on 'Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement'' by Manetti.
2020
-
Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity.
2023
-
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
2021
-
Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'' by Perricone et al.
2021
-
Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans.
2010
-
Rapid destruction of the hip joint in osteoarthritis.
2008
-
Subchondral insufficiency fracture of the femoral head in a patient with systemic lupus erythematosus.
2006
-
Systemic sclerosis following human cytomegalovirus infection.
2002
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
2012
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
2011
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
2010
-
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
2008
-
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
2003
-
Mitochondrial DNA haplogroups and ageing mechanisms in osteoarthritis..
76.
2017
-
Provisional diagnostic criteria for polymyalgia rheumatica: moving beyond clinical intuition?.
71.
2012
-
Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes..
69.
2010
-
When does rheumatoid arthritis start and can it be stopped before it does?.
69.
2010
-
Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress.
2020
-
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.
2019
-
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.
2019
-
A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis.
2012
-
Diagnosis and management of adult onset Still's disease.
2005
-
Subchondral avascular necrosis: a common cause of arthritis.
1990
-
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets.
2023
-
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.
2020
-
Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries.
2012
-
Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade.
2010
-
Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure.
1999